Vancouver, Canada - September 26, 2018 - Aspect Biosystems, a leader in the field of 3D bioprinting and tissue engineering, is pleased to announce the appointment of Spiro Getsios as its new Vice President of Tissue Engineering. Spiro joins Aspect following his role as Director of Biology at GlaxoSmithKline and over 10 years as faculty member at Northwestern University, Feinberg School of Medicine. In his new role, Spiro will be instrumental in driving Aspect’s bioprinted tissue and regenerative medicine R&D strategy. He will manage the advancement of internal tissue engineering programs and focus on expanding Aspect’s portfolio of best-in-class preclinical disease models and implantable therapeutic tissues.
“Spiro joins us with a highly relevant pharmaceutical industry background, proven scientific track record, and deep passion for tissue engineering,” said Tamer Mohamed, Aspect’s President and CEO. “Beyond his unique combination of industry and academic experience, Spiro brings tremendous leadership and R&D management capabilities that will be a big asset to our team. He is joining Aspect at a pivotal stage of growth as we expand our tissue R&D programs and internal pipeline of therapeutic tissues.We are thrilled to welcome him to our leadership team.”
“I am excited to be joining an inspired team of entrepreneurial scientists and business leaders who are wholly committed to delivering on the therapeutic potential of 3D bioprinting technology for drug discovery and regenerative medicine,” said Spiro Getsios. “Aspect Biosystems’ meticulously designed bioprinting platform will enable the development of robust and architecturally complex human tissues for more faithful testing of new medicines and as fit-for-purpose organ replacement parts where there remains a huge, unmet biomedical need.”
Spiro was trained as a reproductive and developmental biologist at the University of British Columbia prior to pursuing a postdoctoral fellowship in cell biology at Northwestern University, Feinberg School of Medicine in Chicago, IL. At Northwestern, Spiro rose to the rank of a tenured Associate Professor of Dermatology and Director of Skin Tissue Engineering while securing federal and industrial funding for his team’s research on cell-cell adhesion and communication systems. In 2016, Spiro joined GlaxoSmithKline Pharmaceuticals in Collegeville, PA as a Director of Biology with a focus on delivering preclinical models for drug discovery and development. He is an author on >60 research publications and currently an adjunct Associate Professor of Dermatology at the University of Pennsylvania, Perelman School of Medicine.
Aspect Biosystems is a privately held biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering. The company’s proprietary Lab-on-a-Printer™ platform technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine. In addition to its internal tissue development programs,Aspect is focused on strategically partnering with pharmaceutical and biotechnology companies, as well as academic researchers, to create physiologically and commercially relevant tissues. These tissues are used for impactful applications in therapeutic discovery and regenerative medicine. www.aspectbiosystems.com